83 related articles for article (PubMed ID: 19621718)
1. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study.
Uggeri F; Caprotti R; De Grate L; Crippa S; Nobili C; Penati C; Romano F
Hepatogastroenterology; 2009; 56(91-92):861-5. PubMed ID: 19621718
[TBL] [Abstract][Full Text] [Related]
2. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
3. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
4. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
Angelini C; Bovo G; Muselli P; Mussi C; Crippa S; Caprotti R; Uggeri F
Hepatogastroenterology; 2006; 53(67):141-4. PubMed ID: 16506394
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
6. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
Romano F; Uggeri F; Crippa S; Di Stefano G; Scotti M; Scaini A; Caprotti R; Uggeri F
J Exp Clin Cancer Res; 2004 Jun; 23(2):195-200. PubMed ID: 15354402
[TBL] [Abstract][Full Text] [Related]
7. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery.
Caprotti R; Brivio F; Fumagalli L; Nobili C; Degrate L; Lissoni P; Parolini D; Messina G; Colciago M; Scotti M; Uggeri F
Anticancer Res; 2008; 28(3B):1951-4. PubMed ID: 18630487
[TBL] [Abstract][Full Text] [Related]
8. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.
Degrate L; Nobili C; Franciosi C; Caprotti R; Brivio F; Romano F; Leone BE; Trezzi R; Uggeri F
Langenbecks Arch Surg; 2009 Jan; 394(1):115-21. PubMed ID: 18670745
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
11. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
[TBL] [Abstract][Full Text] [Related]
12. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
13. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
[TBL] [Abstract][Full Text] [Related]
14. Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients.
Cerea K; Romano F; Bravo AF; Motta V; Uggeri F; Brivio F; Fumagalli LA; Uggeri F
J Surg Oncol; 2001 Sep; 78(1):32-7. PubMed ID: 11519066
[TBL] [Abstract][Full Text] [Related]
15. Radical surgery does not recover immunodeficiency associated with gastric cancer.
Romano F; Caprotti R; Bravo AF; Conti M; Colombo G; Piacentini G; Uggeri F; Uggeri F
J Exp Clin Cancer Res; 2003 Jun; 22(2):179-83. PubMed ID: 12866567
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications.
Brivio F; Lissoni P; Perego MS; Lissoni A; Fumagalli L
J Biol Regul Homeost Agents; 2001; 15(4):370-4. PubMed ID: 11860226
[TBL] [Abstract][Full Text] [Related]
19. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.
Golcher H; Brunner T; Grabenbauer G; Merkel S; Papadopoulos T; Hohenberger W; Meyer T
Eur J Surg Oncol; 2008 Jul; 34(7):756-64. PubMed ID: 18191528
[TBL] [Abstract][Full Text] [Related]
20. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
